131374-93-1 Usage
Uses
Used in Catalysis Industry:
2-(Aminomethyl)cyclobutyl]methanamine 2-hydroxypropanoic acid platinum salt is used as a catalytic agent for its potential to facilitate various chemical reactions. The presence of the platinum metal center and the organic ligands may contribute to its catalytic activity, making it a candidate for use in industrial processes that require efficient catalysts.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-(Aminomethyl)cyclobutyl]methanamine 2-hydroxypropanoic acid platinum salt may be utilized as a precursor or intermediate in the synthesis of pharmaceutical compounds. Its unique structure could offer novel binding properties or reactivity that could be harnessed in the development of new drugs.
Used in Materials Science:
2-(Aminomethyl)cyclobutyl]methanamine 2-hydroxypropanoic acid platinum salt is used as a component in the development of new materials with specific properties. 2-(Aminomethyl)cyclobutyl]methanamine 2-hydroxypropanoic acid platinum salt's platinum content and organic ligands could contribute to the creation of materials with unique electronic, optical, or mechanical characteristics, suitable for various applications in technology and industry.
Check Digit Verification of cas no
The CAS Registry Mumber 131374-93-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,3,7 and 4 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 131374-93:
(8*1)+(7*3)+(6*1)+(5*3)+(4*7)+(3*4)+(2*9)+(1*3)=111
111 % 10 = 1
So 131374-93-1 is a valid CAS Registry Number.
InChI:InChI=1/C6H14N2.C3H6O3.Pt/c7-3-5-1-2-6(5)4-8;1-2(4)3(5)6;/h5-6H,1-4,7-8H2;2,4H,1H3,(H,5,6);
131374-93-1Relevant articles and documents
Anhydrous lobaplatin crystal, preparation method and pharmaceutical applications thereof
-
Paragraph 0298-0301, (2020/03/06)
The invention relates to an anhydrous lobaplatin crystal, a preparation method and pharmaceutical applications thereof, wherein the crystal form of lobaplatin is beta, the diffraction peaks exist at 2[theta] value of about 8.65, 17.34, 18.44, 19.53, 20.42, 21.02, 24.75, 25.47, 26.15, 27.82, 28.77, 30.30, 31.6594, 32.1970, 33.09, 35.10, 36.36, 38.45 and 39.51 in PXRD spectrum, and the error range of the 2[theta] value is 0.2. According to the invention, the preparation method comprises: adding lobaplatin trihydrate into DMSO, crystallizing for 15-20 h at 5-10 DEG C or -20 DEG C to-30 DEG C, precipitating the crystal, removing the solvent, and drying to obtain the crystal; and the prepared crystal is suitable for preparing various forms of pharmaceutical preparations and storing and using, and can be well used for treating cancers such as breast cancer, small cell lung cancer or chronic myelocytic leukemia.
